# Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

> **NCT03765073** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1208 (actual)

## Conditions studied

- Group B Streptococcus Infections

## Interventions

- **BIOLOGICAL:** Multivalent Group B streptococcus vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03765073
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 1208 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765073, "Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT03765073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*